TEL: +86-21-50180596 Email: sales@biopharmaleader.com

Search

Contact Us

Tel: 0086 21 50180596

Fax: 0086 21 57758967

Mob: 0086 18721201413

E-mail:sales@biopharmaleader.com

Exhibition
Home > Exhibition > Content

Eluxadoline news

Shanghai Biopharmaleader Co.,Ltd | Updated: Jan 07, 2017

Eluxadoline, also known as JNJ-27018966, is a novel, orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use by the United States Food and Drug Administration on May 27, 2015. Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.

Synonym: JNJ-27018966; JNJ27018966; JNJ 27018966; Eluxadoline, brand name: Viberzi.

IUPAC/Chemical Name: 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid

SMILES Code: CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N


Shanghai Biopharmaleader Co.,Ltd is a young and innovative company specializing in the design and synthesis of organic compounds for pharmaceutical, medicinal chemistry, biotechnology, drug discovery industries and world's top universities.

We specialize in complex, multi-stage custom synthesis and process research. We are capable of supplying mg to multiple-ton quantities of key pharmaceutical intermediates and Bioactive Molecules, pre-clinical and high-throughput screening compounds, analogues, building blocks.

More information on Eluxadoline   http://www.biopharmaleader.net/ap/


Shanghai Biopharmaleader Co.,Ltd